Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31178384 | 0.84 | DGAT1 (0.33) | DGAT2OPRK1DGAT1POLBHCAR2 | |
| SCHEMBL25317296 | 0.84 | DGAT1 (0.33) | DGAT2OPRK1DGAT1POLBHCAR2 | |
| SCHEMBL31356591 | 0.80 | OPRK1 (0.42) | DGAT2OPRK1DGAT1HSD17B10POLB | |
| SCHEMBL9648890 | 0.80 | OPRK1 (0.42) | DGAT2OPRK1DGAT1HSD17B10POLB | |
| SCHEMBL19209859 | 0.79 | ALDH1A1 (0.33) | OPRK1FFAR1ALDH1A1 | |
| SCHEMBL29498804 | 0.78 | NAPRT (0.46) | OPRK1DGAT1HSD17B10POLBHCAR2 | |
| SCHEMBL1516793 | 0.78 | NAPRT (0.46) | OPRK1DGAT1HSD17B10POLBHCAR2 | |
| SCHEMBL26023823 | 0.78 | DGAT1 (0.36) | DGAT2OPRK1DGAT1POLBHCAR2 | |
| SCHEMBL21815554 | 0.77 | ALDH1A1 (0.35) | DGAT2OPRK1DGAT1POLBHCAR2 | |
| SCHEMBL25335179 | 0.77 | DGAT1 (0.52) | DGAT1POLBHCAR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504709-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119137103-A | CDK9 inhibitors | 拜奥列司治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240150322-A1 | CDK9 Inhibitors | BAERENKRAFT THERAPEUTICS, LLC | 2024-05-09 | — | — | US | disclosed |
| WO-2023196518-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196518-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2022159745-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | DGAT2 275/4885OPRK1 1826/4885DGAT1 565/4885 |
| US-20240150322-A1 | CDK9 Inhibitors | CDK9, CDK19, CDK1 | DGAT2 4834/4885OPRK1 2419/4885DGAT1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.